NEW
YORK, July 3, 2024 /PRNewswire/ -- The
global anti-inflammatory therapeutics market size is estimated
to grow by USD 38.7 billion from
2024-2028, according to Technavio. The market is estimated to grow
at a CAGR of over 6.3% during the forecast period. Increase in
off-label use is driving market growth, with a trend
towards emergence of novel anti-inflammatory drugs.
However, risks and uncertainties associated with
anti-inflammatory biologics poses a challenge. Key market players
include AbbVie Inc., Alvogen Iceland ehf, Amgen Inc., Amneal
Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International
GmbH, Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cipla
Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Ferring BV,
GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd.,
Viatris Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical
Industries Ltd., and Novartis AG.
![Technavio has announced its latest market research report titled Global anti-inflammatory therapeutics market 2024-2028 Technavio has announced its latest market research report titled Global anti-inflammatory therapeutics market 2024-2028](https://mma.prnewswire.com/media/2452788/Technavio__announced_its_latest_market_research_report_titled_Global_anti_inflammatory_therapeuti.jpg)
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Application (RA,
Psoriasis, and MS), Drug Class (Anti-inflammatory biologicals,
Corticosteroids, and NSAIDs), and Geography (North America, Europe,
Asia, and Rest of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
AbbVie Inc., Alvogen
Iceland ehf, Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG,
Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co.,
Cadila Pharmaceuticals Ltd., Cipla Inc., Eli Lilly and Co., F.
Hoffmann-La Roche Ltd., Ferring BV, GlaxoSmithKline Plc, Johnson
and Johnson Services Inc., Lupin Ltd., Viatris Inc., Pfizer Inc.,
Sanofi SA, Teva Pharmaceutical Industries Ltd., and Novartis
AG
|
Key Market Trends Fueling Growth
The anti-inflammatory therapeutics market is experiencing
significant growth due to the development of JAK pathway
inhibitors. These drugs, such as XELJANZ (Tofacitinib), target the
JAK/STAT signaling pathway, which plays a crucial role in immune
response and cellular processes. By inhibiting this pathway, there
is a decrease in the level of inflammation, leading to the
treatment of various chronic inflammatory diseases like
Inflammatory Bowel Disease (IBD) and Rheumatoid Arthritis (RA).
Ongoing clinical trials for JAK inhibitors present ample
opportunities for market expansion during the forecast
period.
The Anti-Inflammatory Therapeutics market is experiencing
significant growth due to the increasing prevalence of inflammatory
diseases. Biologics and small molecules are the two main categories
driving market expansion. Chronic diseases such as arthritis,
inflammatory bowel disease, and psoriasis are major indications.
Therapies like corticosteroids, NSAIDs, and DMARDs are commonly
used. Recent trends include the development of biosimilars and the
use of artificial intelligence in drug discovery. The market is
expected to continue growing due to the unmet medical need and
ongoing research. The future of anti-inflammatory therapeutics lies
in the development of more effective and targeted
treatments.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- The global anti-inflammatory therapeutics market faces
challenges due to the complex and costly processes involved in
producing biological products. Government regulations pose
significant hurdles, impacting the transport and use of raw
materials like cell lines. Manufacturing facilities require
specialized validation and adherence to stringent quality
guidelines. Biologics, derived from living organisms, are more
expensive than traditional pharmaceuticals. For instance, HUMIRA,
an anti-inflammatory biological product, is synthesized using
recombinant DNA technology and requires specific storage
conditions. Ensuring a consistent supply of raw materials,
adherence to regulations, and proper storage are crucial for market
growth.
- The Anti-Inflammatory Therapeutics Market faces several
challenges in the implementation and adoption of its products.
These include the high cost of development and production, the need
for long-term treatment plans, and the presence of side effects.
Additionally, the regulatory environment is complex, with strict
guidelines for safety and efficacy. Furthermore, the market is
competitive, with many players vying for market share. The use of
natural ingredients and personalized treatment plans are trends
that are gaining popularity to address these challenges. The market
requires continuous innovation to provide effective and affordable
solutions for patients.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This anti-inflammatory therapeutics market report extensively
covers market segmentation by
- Application
- 1.1 RA
- 1.2 Psoriasis
- 1.3 MS
- Drug Class
- 2.1 Anti-inflammatory biologicals
- 2.2 Corticosteroids
- 2.3 NSAIDs
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 RA- The anti-inflammatory therapeutics market is
experiencing growth due to the increasing prevalence of autoimmune
diseases, particularly rheumatoid arthritis (RA). According to the
Centers for Disease Control and Prevention (CDC), approximately
54.4 million US adults have arthritis, with RA being one of the
most common types. By 2040, this number is projected to reach 78
million. The market growth is driven by the high demand for
anti-inflammatory drugs to manage the joint pain and inflammation
associated with RA. Advances in diagnostic technology are also
intensifying market growth.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data (2018 -
2022) - Download a Sample Report
Research Analysis
The Anti-Inflammatory Therapeutics Market encompasses a range of
treatments designed to reduce inflammation and manage various
chronic illnesses, including autoimmune diseases, respiratory
diseases, and infectious illnesses. Anti-inflammatory biologics,
such as monoclonal antibodies, play a significant role in this
market. Biosimilars, which are cost-effective alternatives to
original biologics, are also gaining popularity. Conventional
medications, like nonsteroidal anti-inflammatory drugs (NSAIDs),
prostaglandin modulators, and corticosteroids, continue to be
widely used for pain relief and swelling. However, the negative
effects associated with long-term use of these conventional
medications have led to an increased focus on anti-inflammatory
therapeutics. The incidence of chronic illnesses, such as
rheumatoid arthritis, migraines, and headaches, is on the rise,
driving market growth. The patent expiration of major
anti-inflammatory biologics, like Remicade, is leading to increased
competition and innovation in the market. The current global health
crisis caused by beta coronavirus, pneumonia, and the resulting
cytokine storm, has further highlighted the importance of effective
anti-inflammatory therapeutics for managing acute respiratory
distress. Pharmaceuticals continue to invest in research and
development to address the unmet needs in this market.
Market Research Overview
The Anti-Inflammatory Therapeutics Market refers to the global
industry dedicated to developing and supplying medications and
treatments that reduce inflammation in the body. These therapeutics
are essential in managing various chronic conditions such as
arthritis, asthma, and inflammatory bowel diseases. The market is
driven by the increasing prevalence of inflammatory diseases
worldwide and the growing demand for effective and safe
anti-inflammatory treatments. Key therapeutic classes include
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids,
and Biologics. Innovations in research and development, as well as
advancements in delivery systems, are expected to shape the future
of the Anti-Inflammatory Therapeutics Market.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Application
-
- Drug Class
-
- Anti-inflammatory Biologicals
- Corticosteroids
- NSAIDs
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anti-inflammatory-therapeutics-market-size-is-set-to-grow-by-usd-38-7-billion-from-2024-2028--increase-in-off-label-use-to-boost-the-market-growth-technavio-302188035.html
SOURCE Technavio